French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, 59 Boulevard Pinel, 69677, Bron Cedex, France.
SynatAc Team, Institut NeuroMyoGène, INSERM U1217, CNRS, UMR 5310, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.
Cerebellum. 2022 Aug;21(4):573-591. doi: 10.1007/s12311-021-01363-3. Epub 2022 Jan 12.
Major advances in our knowledge concerning autoimmune and paraneoplastic cerebellar ataxias have occurred in the last 20 years. The discovery of several neural antibodies represents an undeniable contribution to this field, especially those serving as good biomarkers of paraneoplastic neurological syndromes and those showing direct pathogenic effects. Yet, many patients still lack detectable or known antibodies, and also many antibodies have only been reported in few patients, which makes it difficult to define in detail their clinical value. Nevertheless, a notable progress has additionally been made in the clinical characterization of patients with the main neural antibodies, which, although typically present with a subacute pancerebellar syndrome, may also show either hyperacute or chronic onsets that complicate the differential diagnoses. However, prodromal and transient features could be useful clues for an early recognition, and extracerebellar involvement may also be highly indicative of the associated antibody. Moreover, important advances in our understanding of the pathogenesis of cerebellar ataxias include the description of antibody effects, especially those targeting cell-surface antigens, and first attempts to isolate antigen-specific T-cells. Furthermore, genetic predisposition seems relevant, although differently involved according to cancer association, with particular HLA observed in non-paraneoplastic cases and genetic abnormalities in the tumor cells in paraneoplastic ones. Finally, immune checkpoint inhibitors used as cancer immunotherapy may rarely induce cerebellar ataxias, but even this undesirable effect may in turn serve to shed some light on their physiopathology. Herein, we review the principal novelties of the last 20 years regarding autoimmune and paraneoplastic cerebellar ataxias.
在过去的 20 年中,我们对自身免疫性和副肿瘤性小脑性共济失调的认识取得了重大进展。几项神经抗体的发现无疑为此领域做出了贡献,尤其是那些作为副肿瘤性神经综合征良好生物标志物的抗体,以及那些具有直接致病作用的抗体。然而,许多患者仍然缺乏可检测或已知的抗体,而且许多抗体仅在少数患者中报告过,这使得难以详细定义它们的临床价值。尽管如此,在主要神经抗体患者的临床特征方面仍取得了显著进展,尽管这些患者通常表现为亚急性全小脑综合征,但也可能出现超急性或慢性发作,从而使鉴别诊断变得复杂。然而,前驱和短暂的特征可能是早期识别的有用线索,并且脑外受累也可能高度提示相关抗体。此外,对小脑性共济失调发病机制的理解方面的重要进展包括对抗体作用的描述,特别是针对细胞表面抗原的抗体作用,以及首次尝试分离抗原特异性 T 细胞。此外,遗传易感性似乎很重要,尽管根据癌症相关性的不同而有所不同,在非副肿瘤性病例中观察到特定的 HLA,而在副肿瘤性病例中观察到肿瘤细胞的遗传异常。最后,作为癌症免疫疗法的免疫检查点抑制剂可能很少会引起小脑性共济失调,但即使这种不良影响也可能反过来有助于阐明其病理生理学。在此,我们回顾了过去 20 年中自身免疫性和副肿瘤性小脑性共济失调的主要新发现。